Tarsus Pharmaceuticals (TARS)

• Market cap: $3.21B
• 1 day: -0.46%
• 5 days: 14.86%
• 1 month: 10.81%
• 3 months: -5.55%
• 6 months: 30.61%
• Year to date: -6.5%
• 1 year: 73.41%
• 5 years: 105.27%
• 10 years: 266.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Employees: 323